Long-term experience with alendronate in the treatment of osteoporosis.
Osteoporosis is characterised by increased bone turnover, low bone mass and impaired bone microarchitecture, leading to increased fracture risk. Effective anticatabolic therapies decrease fracture risk by reducing the rate of bone turnover, thereby maintaining bone microarchitecture and increasing bone mineral density. At present, potent oral bisphosphonates, such as alendronate (FOSAMAX; Merck & Co.), are preferred for the treatment of osteoporosis. Long-term clinical trial data demonstrate that alendronate is effective and generally well tolerated. Results from head-to-head studies and meta-analyses suggest that alendronate is more effective than certain other anticatabolic agents in the treatment of patients with osteoporosis.
Hochberg
Marc C
MC
Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Rizzoli
René
R
D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000378:metabolism; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid
D050071:Bone Density Conservation Agents; D020849:Raloxifene Hydrochloride; D002116:Calcitonin; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate